Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
BackgroundThe relationships of the coronavirus disease 2019 (COVID-19) vaccination with reactogenicity and the humoral immune response are important to study. The current study aimed to assess the reactogenicity and immunogenicity of the Pfizer and AstraZeneca COVID-19 vaccines among adults in Madin...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.794642/full |
| _version_ | 1831730910646501376 |
|---|---|
| author | Waleed H. Mahallawi Walaa A. Mumena |
| author_facet | Waleed H. Mahallawi Walaa A. Mumena |
| author_sort | Waleed H. Mahallawi |
| collection | DOAJ |
| description | BackgroundThe relationships of the coronavirus disease 2019 (COVID-19) vaccination with reactogenicity and the humoral immune response are important to study. The current study aimed to assess the reactogenicity and immunogenicity of the Pfizer and AstraZeneca COVID-19 vaccines among adults in Madinah, Saudi Arabia.MethodsA cross-sectional study, including 365 randomly selected adult Pfizer or AstraZeneca vaccine recipients who received a homologous prime-boost vaccination between February 1st and June 30th, 2021. Data of height and weight were collected to assess the weight status of percipients. An evaluation of seropositivity for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies was assessed using enzyme-linked immunosorbent assay (ELISA).ResultsAmong the participants, 69% (n = 250) reported at least one vaccine-related symptom. Pain at the injection site was the most frequently reported vaccine-related symptom. The mean total score for vaccine-related symptoms was significantly higher among participants who received the AstraZeneca vaccine, women, and participants with no previous COVID-19 infection (p < 0.05). Spike-specific IgG antibodies were detected in 98.9% of participants after the receipt of two vaccine doses, including 99.5% of Pfizer vaccine recipients and 98.3% of AstraZeneca vaccine recipients. Significantly, higher proportions of participants in the <35-year age group developed a humoral immune response after the first vaccine dose compared with the participants in other age groups.ConclusionParticipants who received the Pfizer COVID-19 vaccine reported fewer vaccine-related complications compared with those who received the AstraZeneca COVID-19 vaccine, but no serious side effects were reported in response to either vaccine. Health status and age were factors that may influence COVID-19 vaccine effectiveness for the generation of antibodies against the SARS-CoV-2 spike protein. |
| first_indexed | 2024-12-21T09:54:54Z |
| format | Article |
| id | doaj.art-c757bb9b89664764bc9d7f9df25a3bf3 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-21T09:54:54Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c757bb9b89664764bc9d7f9df25a3bf32022-12-21T19:08:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-12-011210.3389/fimmu.2021.794642794642Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 VaccinesWaleed H. Mahallawi0Walaa A. Mumena1Medical Laboratory Technology Department, College of Applied Medical Sciences, Taibah University, Madinah, Saudi ArabiaClinical Nutrition Department, College of Applied Medical Sciences, Taibah University, Madinah, Saudi ArabiaBackgroundThe relationships of the coronavirus disease 2019 (COVID-19) vaccination with reactogenicity and the humoral immune response are important to study. The current study aimed to assess the reactogenicity and immunogenicity of the Pfizer and AstraZeneca COVID-19 vaccines among adults in Madinah, Saudi Arabia.MethodsA cross-sectional study, including 365 randomly selected adult Pfizer or AstraZeneca vaccine recipients who received a homologous prime-boost vaccination between February 1st and June 30th, 2021. Data of height and weight were collected to assess the weight status of percipients. An evaluation of seropositivity for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies was assessed using enzyme-linked immunosorbent assay (ELISA).ResultsAmong the participants, 69% (n = 250) reported at least one vaccine-related symptom. Pain at the injection site was the most frequently reported vaccine-related symptom. The mean total score for vaccine-related symptoms was significantly higher among participants who received the AstraZeneca vaccine, women, and participants with no previous COVID-19 infection (p < 0.05). Spike-specific IgG antibodies were detected in 98.9% of participants after the receipt of two vaccine doses, including 99.5% of Pfizer vaccine recipients and 98.3% of AstraZeneca vaccine recipients. Significantly, higher proportions of participants in the <35-year age group developed a humoral immune response after the first vaccine dose compared with the participants in other age groups.ConclusionParticipants who received the Pfizer COVID-19 vaccine reported fewer vaccine-related complications compared with those who received the AstraZeneca COVID-19 vaccine, but no serious side effects were reported in response to either vaccine. Health status and age were factors that may influence COVID-19 vaccine effectiveness for the generation of antibodies against the SARS-CoV-2 spike protein.https://www.frontiersin.org/articles/10.3389/fimmu.2021.794642/fullreactogenicityimmunogenicityPfizerAstraZenecavaccinesSaudi Arabia |
| spellingShingle | Waleed H. Mahallawi Walaa A. Mumena Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines Frontiers in Immunology reactogenicity immunogenicity Pfizer AstraZeneca vaccines Saudi Arabia |
| title | Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines |
| title_full | Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines |
| title_fullStr | Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines |
| title_full_unstemmed | Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines |
| title_short | Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines |
| title_sort | reactogenicity and immunogenicity of the pfizer and astrazeneca covid 19 vaccines |
| topic | reactogenicity immunogenicity Pfizer AstraZeneca vaccines Saudi Arabia |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.794642/full |
| work_keys_str_mv | AT waleedhmahallawi reactogenicityandimmunogenicityofthepfizerandastrazenecacovid19vaccines AT walaaamumena reactogenicityandimmunogenicityofthepfizerandastrazenecacovid19vaccines |